<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085617</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000667211</org_study_id>
    <secondary_id>UCL-08-0167</secondary_id>
    <secondary_id>EU-21009</secondary_id>
    <secondary_id>2009-012717-22</secondary_id>
    <secondary_id>UCL-UKALL14</secondary_id>
    <secondary_id>MREC-09-H0711-90</secondary_id>
    <secondary_id>NCRI-UCL-08-0167</secondary_id>
    <secondary_id>CRUK-C27995-A9609</secondary_id>
    <nct_id>NCT01085617</nct_id>
  </id_info>
  <brief_title>Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
  <acronym>UKALL14</acronym>
  <official_title>A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as&#xD;
      rituximab, can block cancer growth in different ways. Some block the ability of cancer cells&#xD;
      to grow and spread. Others find cancer cells and help kill them or carry cancer-killing&#xD;
      substances to them. It is not yet known which regimen of combination chemotherapy given&#xD;
      together with or without monoclonal antibodies is more effective in treating patients with&#xD;
      newly diagnosed acute lymphoblastic leukemia.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying standard chemotherapy to see how well it&#xD;
      works when given together with or without rituximab, and with or without nelarabine in&#xD;
      treating patients with newly diagnosed acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine if the addition of a monoclonal antibody (none vs. rituximab) improves&#xD;
           event-free survival (EFS) in patients with newly diagnosed precursor B-cell acute&#xD;
           lymphoblastic leukemia (ALL).&#xD;
&#xD;
        -  To determine if the addition of nelarabine improves outcome for patients with T-cell&#xD;
           ALL.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the tolerability of pegaspargase in induction therapy of all patients.&#xD;
&#xD;
        -  To compare anti-asparaginase antibody levels in patients with B-lineage ALL.&#xD;
&#xD;
        -  To determine whether risk-adapted introduction of unrelated donor hematopoietic stem&#xD;
           cell transplantation (HSCT) (myeloablative conditioning in patients ≤ 40 years old and&#xD;
           non-myeloablative conditioning in patients &gt; 40 years old) results in greater EFS for&#xD;
           patients at highest risk of relapse.&#xD;
&#xD;
        -  To compare the efficacy of two schedules (standard vs collapsed) of palifermin in&#xD;
           preventing severe mucosal toxicity in patients treated with etoposide, total-body&#xD;
           irradiation, and HSCT-conditioning therapy.&#xD;
&#xD;
        -  To assess the late effects of this treatment in these patients.&#xD;
&#xD;
        -  To identify and describe some of the adverse physical and psychosocial consequences of&#xD;
           this disease and its treatment.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. There are 3 randomizations at different timepoints in&#xD;
      the trial, each patient undergoes at least 1 but no more than 2 randomizations.&#xD;
&#xD;
        -  Part 1 standard induction therapy (all patients*, weeks 1-4): Patients receive&#xD;
           daunorubicin hydrochloride IV over 20 minutes and vincristine sulfate IV over 5-10&#xD;
           minutes on days 1, 8, 15, and 22; oral dexamethasone once a day on days 1-5, 8-11, and&#xD;
           15-18; pegaspargase IV over 1-2 hours on days 4 and 18; and methotrexate intrathecally&#xD;
           (IT) on day 14.&#xD;
&#xD;
      NOTE: *Patients with Philadelphia-positive (Ph+) disease should also receive oral imatinib&#xD;
      mesylate once a day on days 1-28.&#xD;
&#xD;
        -  Randomized concurrent monoclonal antibody therapy (for patients with precursor B-cell&#xD;
           acute lymphoblastic leukemia [ALL]): Patients with precursor B-cell ALL are randomized&#xD;
           to 1 of 4 monoclonal antibody treatment arms (given concurrently with part 1 standard&#xD;
           induction therapy):&#xD;
&#xD;
             -  Arm B1: Patients do not receive any monoclonal antibody therapy.&#xD;
&#xD;
             -  Arm B2 : Patients receive rituximab IV on days 3, 10, 17, and 24.&#xD;
&#xD;
                  -  Part 2 standard induction therapy (all patients*, weeks 5-8): Patients receive&#xD;
                     cyclophosphamide IV over 30 minutes on days 1 and 15; cytarabine IV on days&#xD;
                     2-5, 9-12, 16-19, and 23-26; oral mercaptopurine once a day on days 1-28; and&#xD;
                     methotrexate IT on days 1, 8, 15, and 22.&#xD;
&#xD;
      NOTE: *Patients with Ph+ disease should also receive oral imatinib mesylate once a day on&#xD;
      days 1-30.&#xD;
&#xD;
        -  Randomized subsequent nelarabine therapy (for Patients with T-cell ALL) Patients with&#xD;
           T-cell ALL are randomized to 1 of 2 treatment arms, to be administered after completion&#xD;
           of part 2 standard induction therapy.&#xD;
&#xD;
             -  Arm T1: Patients do not receive any other therapy during induction.&#xD;
&#xD;
             -  Arm T2: Patients receive nelarabine IV over 2 hours on days 1, 3, and 5. Patients&#xD;
                who do not achieve complete remission (CR) after part 2 standard induction therapy&#xD;
                are taken off study.&#xD;
&#xD;
                  -  Intensification/central nervous system prophylaxis (patients not eligible for&#xD;
                     transplant OR patients &gt; 40 years at study entry and eligible for&#xD;
                     transplant)*: Beginning after recovery from part 2 standard induction therapy,&#xD;
                     patients receive high-dose methotrexate IV on days 1 and 15 and pegaspargase&#xD;
                     IV over 1-2 hours on days 2 and 16.&#xD;
&#xD;
      NOTE: *Patients with Philadelphia-positive (Ph+) disease should also receive oral imatinib&#xD;
      mesylate once a day on days 1-28.&#xD;
&#xD;
      Patients eligible for allogeneic hematopoietic stem cell transplantation (HSCT) (i.e., any&#xD;
      patient with an HLA-compatible sibling donor or high risk patients with a molecularly matched&#xD;
      donor) undergo transplantation; patients not eligible for HSCT undergo consolidation followed&#xD;
      by maintenance therapy.&#xD;
&#xD;
        -  Consolidation therapy* (patients not eligible for transplantation):&#xD;
&#xD;
             -  Course 1: Beginning after completion of intensification therapy, patients receive&#xD;
                cytarabine IV and high-dose etoposide IV over 30 minutes on days 1-5, pegaspargase&#xD;
                IV over 1-2 hours on day 5, and methotrexate IT on day 1. Patients proceed to&#xD;
                course 2 beginning 3 weeks after the start of course 1 or when neutrophils recover.&#xD;
&#xD;
             -  Course 2: Patients receive cytarabine IV and high-dose etoposide IV over 30 minutes&#xD;
                on days 1-5 and methotrexate IT on day 1. Patients proceed to course 3 beginning 3&#xD;
                weeks after the start of course 2 or when neutrophils recover.&#xD;
&#xD;
             -  Course 3 (delayed intensification): Patients receive daunorubicin hydrochloride IV&#xD;
                over 20 minutes and vincristine sulfate IV over 5-10 minutes on days 1, 8, 15, and&#xD;
                22; pegaspargase IV over 1-2 hours on day 4; oral dexamethasone once a day on days&#xD;
                1-4, 8-11, 15-18, and 22-25; methotrexate IT on days 2 and 17; cyclophosphamide IV&#xD;
                on day 29; cytarabine IV on days 30-33 and 37-40; and oral mercaptopurine once a&#xD;
                day on days 29-42. Patients proceed to course 4 after neutrophils recover.&#xD;
&#xD;
             -  Course 4: Patients receive cytarabine IV, high-dose etoposide IV, and methotrexate&#xD;
                IT as in course 2.&#xD;
&#xD;
      NOTE: *Patients with Ph+ disease should also receive oral imatinib mesylate once a day on&#xD;
      days 1-7 in courses 1 and 2, on days 2-42 in course 3, and on days 1-8 in course 4.&#xD;
&#xD;
        -  Maintenance therapy (patients not eligible for transplantation): Patients receive&#xD;
           vincristine sulfate IV every 3 months, oral prednisolone once a day on days 1-5 every 3&#xD;
           months, oral mercaptopurine once daily, methotrexate IV or orally once a week, and&#xD;
           methotrexate IT every 3 months for 2 years.&#xD;
&#xD;
        -  Transplant conditioning and allogeneic HSCT:&#xD;
&#xD;
             -  Myeloablative-conditioning and allogeneic HSCT (patients ≤ 40 years old at study&#xD;
                entry): Patients undergo total-body irradiation on days -7 to -4 and receive&#xD;
                high-dose etoposide IV over 4 hours on day -3 or high-dose cyclophosphamide IV over&#xD;
                2 hours on days -3 and -2. Patients then undergo allogeneic HSCT on day 0.&#xD;
&#xD;
      Patients are stratified according to gender, donor (sibling donor vs. matched unrelated&#xD;
      donor), and cellular type of ALL (precursor B-lineage vs. T-lineage). Patients are randomized&#xD;
      to receive 1 of 2 palifermin treatment arms.&#xD;
&#xD;
        -  Arm P1 (standard dose): Patients receive palifermin IV on days -3 to 2.&#xD;
&#xD;
        -  Arm P2 (collapsed dose): Patients receive palifermin IV on days -1 to 2.&#xD;
&#xD;
             -  Non-myeloablative-conditioning and allogeneic HSCT (patients &gt; 40 years old at&#xD;
                study entry): Patients receive fludarabine phosphate IV over 30-60 minutes on days&#xD;
                -7 to -3 and melphalan IV over 90 days on day -1. Recipients of unrelated donor&#xD;
                HSCT also receive alemtuzumab IV over 2 hours on day -2 and -1; recipients of&#xD;
                sibling HSCT receive alemtuzumab IV over 2 hours on day -1. Patients then undergo&#xD;
                allogeneic HSCT on day 0. Patients also receive post transplant methotrexate IT&#xD;
                every 3 months for 2 years.&#xD;
&#xD;
      Patients undergo blood and bone marrow sample collection periodically for correlative&#xD;
      studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed annually.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised phase III trial of standard treatment +/- rituximab for patients with precursor B-cell ALL or nelarabine for patients with T-cell ALL. A further randomisation investigated two schedules of palifermin administration in patients undergoing myeloablative transplant.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from randomisation to relapse or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-asparaginase antibodies in patients treated with monoclonal antibody therapy</measure>
    <time_frame>Throughout treatment</time_frame>
    <description>Antibody levels in sequential samples during pegylated asparaginase treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from randomisation to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>Throughout treatment</time_frame>
    <description>Proportion of patients achieving morphological complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal-residual disease quantification after first phase of induction and post-transplantation</measure>
    <time_frame>Throughout treatment</time_frame>
    <description>Minimal residual disease measured at central laboratory after phase 1 induction and post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate (including bone marrow and CNS relapse)</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients experiencing a bone marrow of CNS relapse after entering complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in CR</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients dying while their ALL is in complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity related to pegaspargase</measure>
    <time_frame>Throughout treatment</time_frame>
    <description>Rates of hypersensitivity, changes to Erwinia, or withdrawal of asparaginase treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucositis score in patients treated with palifermin</measure>
    <time_frame>30 days</time_frame>
    <description>OMQD score, number of doses of methotrexate given, acute GVHD rates</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">811</enrollment>
  <condition>Leukemia</condition>
  <condition>Mucositis</condition>
  <condition>Oral Complications</condition>
  <arm_group>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard chemotherapy for precursor B-cell ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard chemotherapy for T-cell ALL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1 - standard palifermin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P2 - collapsed palifermin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>palifermin</intervention_name>
    <arm_group_label>P1 - standard palifermin</arm_group_label>
    <arm_group_label>P2 - collapsed palifermin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>B2 - Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelarabine</intervention_name>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>B1 - Standard therapy</arm_group_label>
    <arm_group_label>B2 - Rituximab</arm_group_label>
    <arm_group_label>T1 - Standard therapy</arm_group_label>
    <arm_group_label>T2 - Nelarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>P1 - standard palifermin</arm_group_label>
    <arm_group_label>P2 - collapsed palifermin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <arm_group_label>P1 - standard palifermin</arm_group_label>
    <arm_group_label>P2 - collapsed palifermin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed, previously untreated acute lymphoblastic leukemia&#xD;
&#xD;
               -  A pre-phase steroid treatment of 5-7 days is required and can be started prior to&#xD;
                  registration&#xD;
&#xD;
          -  Philadelphia chromosome-negative or -positive patients are eligible&#xD;
&#xD;
          -  No blast transformation of chronic myeloid leukemia&#xD;
&#xD;
          -  No mature B-cell leukemia [i.e., Burkitt disease t(8,14)(q24 ;q32)] or variant c-myc&#xD;
             translocations [e.g., t(2;8)(p12;q24), t(8;22)(q24;q11)]&#xD;
&#xD;
          -  Patients who undergo study transplantation must have HLA-compatible sibling or&#xD;
             unrelated donor&#xD;
&#xD;
               -  8/8 molecular match at -A, -B, -C, and -DR (DQ mismatch is permitted)&#xD;
&#xD;
          -  Patients meeting ≥ 1 the following criteria are considered high-risk:&#xD;
&#xD;
               -  Over 40 years old&#xD;
&#xD;
               -  WBC ≥ 30 x 10^9/L (precursor-B) OR ≥ 100 x 10^9/L (T-lineage)&#xD;
&#xD;
               -  Any 1 or more of the following cytogenetic abnormalities:&#xD;
&#xD;
                    -  t(4;11)(q21;q23)/MLL-AF4&#xD;
&#xD;
                    -  Low hypodiploidy/near triploidy (30-39 chromosomes/60-78 chromosomes)&#xD;
&#xD;
                    -  Complex karyotype (≥ 5 chromosomal abnormalities)&#xD;
&#xD;
                    -  Philadelphia chromosome t(9;22) (q34;q11)/BCR-ABL1 (detected by cytogenetic&#xD;
                       or molecular methods)&#xD;
&#xD;
               -  High-risk minimal-residual disease after completion of part 2 standard induction&#xD;
                  therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing (no nursing during and for 12 months after completion of study&#xD;
             therapy)&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 12 months after&#xD;
             completion of study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adele K. Fielding</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London (UCL) Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1E 6DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-207-830-2833</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral complications</keyword>
  <keyword>mucositis</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>B-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>T-cell adult acute lymphoblastic leukemia</keyword>
  <keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

